TF Capital

Founded 2013

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 30
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 24
Rounds per year 3.75
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 4
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

The venture was found in Asia in China. The main office of represented VC is situated in the Pudong.

The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight ZAI Lab, Antengene Corporation, Asieris Pharmaceuticals. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. This TF Capital works on 22 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 13 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the TF Capital, startups are often financed by Qiming Venture Partners, Sequoia Capital China, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are Qiming Venture Partners, Sinopharm Capital, Sequoia Capital China. In the next rounds fund is usually obtained by Sequoia Capital China, OrbiMed, Lapam Capital.

Besides them, we counted 1 critical employee of this fund in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Allorion Therapeutics

Medical
Pharmaceutical
Therapeutics
$40M24 Nov 2021 Natick, Massachusetts, United States

Abogen Biosciences

Biotechnology
Life Science
$92M08 Apr 2021 Gusu District, Jiangsu, China

Biopharma
Biotechnology
Neuroscience
$100M08 Dec 2020 Shanghai, China

Hanyu Medical

Health Care
Medical
Medical Device
$77M13 Aug 2020 China, Shanghai

EOC Pharma Group

Biopharma
Biotechnology
Health Care
Pharmaceutical
$77M02 Dec 2019 China, Shanghai

Tisenc

Medical
$12M06 Sep 2019 Futian District, Guangdong Province, China

GeneQuantum Healthcare

Health Care
Personal Health
Therapeutics
$15M07 May 2019 China, Beijing

Abbisko Therapeutics

Health Care
Pharmaceutical
Therapeutics
$42M21 Mar 2019 China, Shanghai

Antengene Corporation

Biopharma
Biotechnology
Life Science
Pharmaceutical
$120M02 Jan 2019 China, Shanghai
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Regor Therapeutics Announces Completion of $90 Million Series B Financing

– Regor Therapeutics announced the successful completion of $90m Series B financing.
– The round was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China.
– Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
– Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development.
– Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

Review

  • No reviews are submitted yet.
Related media
Top 20 VC funds in Eastern Asia that took part in the most Early Stage funding rounds in Wellness/Personal Health industry over the recent years
If you have found a spelling error or the data isn’t actual, please, notify us by selecting that text and pressing Ctrl+Enter. Read more
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent TF Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: